Abraxis BioScience
Biotechnology Research • 
Los Angeles, California, United States • 101-200 Employees
Company overview
| Headquarters | Los Angeles, California, United States |
| Websites | |
| NAICS | 541714 |
| Employees | 101-200 |
| Socials |
Key Contacts at Abraxis BioScience
Michael Post
National Sales Director
Chunlin Tao
Director
Micaela Williams
Director Of Manufacturing
Peter Gargiulo
Director
Steve Nowicki
Senior Director, Site Operations
Paul Contreras
It Director
Alissa Oddo
Associate Director Project Management
Shannon Miller
Sr. Director, Qualtiy Operations
James Tzavaras
Director Of Finance
Edith Lee
Sr. Director Operations
Abraxis BioScience Email Formats
Abraxis BioScience uses 1 email format. The most common is {first name}{last name} (e.g., johndoe@mmm.com), used 100% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name}{last name} | johndoe@mmm.com | 100% |
About Abraxis BioScience
Abraxis BioScience is a fully integrated biotechnology company dedicated to delivering progressive therapeutics, such as ABRAXANE, and core technologies that offer patients and medical professionals safer and more effective treatments for cancer and other critical illnesses. Abraxis' portfolio includes the world's first and only protein-based nanoparticle chemotherapeutic compound. Scientists at Abraxis developed its proprietary tumor targeting system known as the nab™ Technology platform, an innovative approach to treating cancer and other critical illnesses. By harnessing the unique natural properties of the human protein albumin, Abraxis' nab technology platform enables the transport and delivery of therapeutic agents to the site of disease. This revolutionary biologically interactive delivery system is being further developed with other water insoluble drugs for their potential use across a broad range of tumors. ABRAXANE® for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin bound), the first U.S. Food and Drug Administration (FDA) approved product to use the nab platform, was launched in 2005 for the treatment of metastatic breast cancer. From the discovery and research phase to development and commercialization, Abraxis BioScience is committed to rapidly enriching the company's pipeline and accelerating the delivery of breakthrough therapies that will transform the lives of the patients who need them. Abraxis, with headquarters in Los Angeles, California, trades on the Nasdaq Global Market under the symbol "ABII". For more information about the company and its products, please visit www.abraxisbio.com.
Abraxis BioScience revenue & valuation
| Annual revenue | $300,000,000 |
| Revenue per employee | $1,631,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $960,000,000 |
| Total funding | No funding |
Employees by Management Level
Total employees: 101-200
Seniority
Employees
Employees by Department
Abraxis BioScience has 97 employees across 15 departments.
Departments
Number of employees
Funding Data
Abraxis BioScience has never raised funding before.
Abraxis BioScience Tech Stack
Discover the technologies and tools that power Abraxis BioScience's digital infrastructure, from frameworks to analytics platforms.
CMS
JavaScript graphics
JavaScript libraries
JavaScript libraries
Analytics
Surveys
SSL/TLS certificate authorities
Web servers
JavaScript libraries
Security
Advertising
Analytics
United Kingdom
Netherlands
China
Frequently asked questions
4.8
40,000 users
